The farnesoid X receptor (FXR) is a nuclear receptor superfamily member and ligand-activated transcription factor. By binding to DNA as a monomer or a heterodimer with the common NR partner, retinoid x receptor (RXR), to FXR response elements, FXR controls the expression of numerous genes. The FXR and FXR genes are the two recognized FXR genes.
FXR is primarily expressed in the liver and small intestine, where it is critical for the metabolism of bile acids, lipids, and glucose. FXR regulates bile acid (BA) synthesis and homeostasis, glucose and lipid metabolism, as well as playing a significant role in intestinal bacterial growth and liver regeneration through its specific target genes.
|Cilofexor, formerly known as GS-9674, is a farnesoid X receptor (FXR) agonist.
|FXR antagonist 1
|FXR antagonist 2
|Gly-β-MCA is a bile acid acting as an oral and potent farnesoid X receptor (FXR) inhibitor with the potential to be usedfor the treatment of metabolic disorders.
|Glyco-Obeticholic acid is an active metabolite of Obeticholic acid formed by a phase II metabolic reaction by conjugating with amino acid glycine.
|Glyco-obeticholic acid-d5 (obeticholic acid impurity 8-d5)
|Obeticholic Acid (6-ECDCA; INT-747)
|Obeticholic Acid (INT747; 6-ECDCA; 6-Ethylchenodeoxycholic acid; trade name Ocaliva), a novel derivative of cholic acid, is a potent,orally bioactive and selectiveagonist of farnesoid X receptor (FXR) with EC50 of 99 nM, and has anticholeretic and anti-inflammatory activities.
|Tauro-Obeticholic acid is an active metabolite of Obeticholic acid(Ocaliva; 6-ECDCA;INT747; 6-Ethylchenodeoxycholic acid) formed by conjugating with taurine, or 2-aminoethanesulfonic acid.
|Tauro-β-muricholic acid-d4 sodium